Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,857.89
(
0.78%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: aslan2772 post# 28334

Saturday, 05/06/2006 12:14:20 PM

Saturday, May 06, 2006 12:14:20 PM

Post# of 257302
>Posurdex/Lucentis combo. It's debatable whether SRDX should follow suit with a similar trial using I-vation.<

What is the debate? If the I-vation monotherapy results look good this fall, I don’t see why SRDX wouldn’t benefit by running a small combination trial with less-frequent Lucentis dosing.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today